



Published in final edited form as:

Bioorg Med Chem Lett. 2007 April 15; 17(8): 2229–2232.

Convenient synthesis and *in vitro* pharmacological activity of 2-thioanalogs of salvinorin A and B

Ruslan V. Bikbulatov^a, Feng Yan^b, Bryan L. Roth^b, and Jordan K. Zjawiony^{a,c}

^a Department of Pharmacognosy, School of Pharmacy, University of Mississippi, University, MS 38677-1848, USA

^b Department of Pharmacology, School of Medicine and Division of Medicinal Chemistry and Natural Products, School of Pharmacy, NIMH Psychoactive Drug Screening Program, University of North Carolina, Chapel Hill, NC 27599, USA

^c National Center for Natural Products Research, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 39677-1848, USA

Abstract

To study drug-receptor interactions, new thio-derivatives of salvinorin A, an extremely potent natural κ -opioid receptor (KOR) agonist, were synthesized. Obtained compounds were examined for receptor binding affinity. Analogs with the same configuration at carbon atom C-2 as in natural salvinorin A showed higher affinity to KOR than their corresponding epimers.

Salvinorin A (**1**) is a neoclerodane diterpenoid with a strong hallucinogenic activity. It has been shown to have a high affinity and selectivity to kappa-opioid receptors (KOR)¹. Salvinorin A is isolated from the psychoactive plant *Salvia divinorum* as a major secondary metabolite, and makes an attractive lead compound for drug development due to its strong effects on human mood and low toxicity.

In the last three years numerous derivatives and analogs of salvinorin A were synthesized showing a broad range of KOR affinities². Synthesis of new analogs of salvinorin A is important for generating new data on the structure of the receptor binding site and for possible changing of a pharmacological profile of action from agonist to antagonist. The wealth of the experimental data collected so far allows for structure-activity relationship conclusions pointing out the crucial importance of the C-2 configuration. Structural modifications of salvinorin A skeleton and functional groups in the other than C-2 positions did not provide compounds with higher affinity. In the course of our work on the molecular mechanism of interaction of salvinorin A to KOR we examined the effects of cysteine-substitution mutagenesis on the binding of salvinorin A along with analogs containing free sulfhydryl group at carbon C-2³. These studies prompted us to find a convenient way to synthesize of 2-thioanalogs of salvinorin A and B.

Recently we reported the synthesis of sulfur analog of salvinorin A, in which the oxygen atom at the side chain at carbon atom C-2 was substituted by a sulfur atom^{2c}. We now report the new method of the synthesis of sulfur analogs of salvinorin A and B epimeric at the C-2 stereogenic center. In our method salvinorin B (**2**) is transformed to 2 β -chloroderivative (**3**) with 65% yield using mild condition of chlorination of alcohols with CCl₄-Ph₃P (Appel

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

reaction). It is an improvement over previously used conditions (SOCl₂/Py) which gives **3** with only 29% yield^{2c}. After 2 hours of refluxing of **2** with CCl₄-Ph₃P the only product formed was **3** with 80% conversion of starting material. The prolonged heating (6 h) moved the reaction to completion but a small amount (14%) of the product of epimerization at carbon C-8 (**4**) appeared (Scheme 1).

Epimerization at C-8 is well known in salvinorin chemistry, although it was previously observed repeatedly in basic and once in acidic conditions^{2e, 2j-n, 4}. The nucleophilic substitution of the chlorine atom in **3** by sulfur-containing reagents may be achieved with inversion or retention of configuration at C-2. Reaction of **3** with sodium hydrogen sulfide (NaSH) in methanol and dimethylformamide produces a thiol **5**, while the reaction with potassium thioacetate in acetone^{2c} provides sulfur analog of salvinorin A (**6**) (Scheme 2).

The formation of thiol **5** from **3** is accompanied with several side products. To avoid this, the deacetylation of thioacetate **6** with NaSMe was chosen as cleaner and more effective method of the synthesis of **5**. Deacetylation with sodium thiomethoxide^{5a} proved to be advantageous in our case over the other known methods of hydrolysis of thioacetate group^{5b-f}. The structure of compound **5** was confirmed by spectroscopic analysis (NMR) and high resolution mass spectrometry (HRMS)⁶ as well as by chemical re-acetylation to thioacetate **6**. ¹HNMR spectrum of **5** showed the characteristic doublet of doublets of H-2 due to the coupling with two protons at C-3. The large coupling constants for H-2 and H-3 protons of **5** ($J=6$ Hz and 12Hz) implied the β -orientation of H-2 and hence the desired α -configuration at C-2. The presence of thiol group was also confirmed by characteristic color reaction with Ellman's reagent (DTNB).

The thioacetate **7** was obtained from triflated salvinorin B by reaction with potassium thioacetate in acetone at -20°C ⁷. In these conditions the nucleophilic substitution occurred with inversion of configuration producing 2 β -epimer (**7**) of compound **6**. Deacetylation of **7** in analogous conditions⁸ described above for **6** yielded 2 β -thiosalvinorin B (**8**) (Scheme 3).

Conducted NMR and HRMS analyses confirmed the structure of compounds **7** and **8**⁹. In this case the coupling constants between H-2 and H-3 were smaller ($J=2$ Hz and 5Hz for **7**) and corresponded well with calculated values for the dihedral angles H2 α -C2-C3-H3 α and H2 α -C2-C3-H3 β indicating the β -configuration at C-2.

Compounds **5–8** were evaluated for affinity to κ -opioid receptor (KOR) at the NIMH-sponsored Psychoactive Drug Screening Program at University of North Carolina at Chapel Hill using radioligand binding assays. The assays were conducted according to the procedure described earlier^{1,20}. The results are presented in Table 1.

In conclusion, we were able to obtain new sulfur analogs of salvinorin A and B with "natural" (α) and inverted (β) configurations at carbon atom C-2. Thioanalogs with the same configuration at C-2 as in natural salvinorin A showed higher affinity to KOR than their corresponding epimers. Readily available 2 β -chlorosalvinorin B (**3**) may serve as a convenient intermediate for the synthesis of various new analogs modified at C-2 position, retaining α -configuration of natural salvinorin A.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

Authors would like to acknowledge Dr. Jeremy Stewart for his valuable suggestions and Kelly Thomas and Lukasz Kutrzeba for help in extraction of salvinorin A from plant material.


This work was supported by NIH grants P20 RR 021929-01 (Center of Research Excellence in Natural Products Neuroscience), and R01 DA017204, and conducted in a facility constructed with support from research facilities improvement program grant C06 RR-14503-01 from National Center for Research Resources, National Institutes of Health, Bethesda, MD, USA.

References and notes

- Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB. *Proc Natl Acad Sci* 2002;99:11934. [PubMed: 12192085]
- (a) Lee DYW, He M, Liu-Chen L-Y, Wang Y, Li J-G, Xu W, Ma Z, Carlezon WA Jr, Cohen B. *Biorg Med Chem Lett* 2006;16:5498. (b) Beguin C, Richards MR, Li JG, Wang Y, Xu W, Liu-Chen LY, Carlezon WA, Cohen BM. *Biorg Med Chem Lett* 2006;16:4679. (c) Stewart DJ, Fahmy H, Roth BL, Yan F, Zjawiony JK. *Arzneimittel Forschung Drug Research* 2006;56:269. [PubMed: 16724512] (d) Tidgewell K, Harding WW, Lozama A, Cobb H, Shah K, Kannan P, Dersch CM, Parrish D, Deschamps JR, Rothman RB, Prisinzano TE. *J Nat Prod* 2006;69:914. [PubMed: 16792410] (e) Harding WW, Schmidt M, Tidgewell K, Kannan P, Holden KG, Dersch CM, Rothman RB, Prisinzano TE. *Biorg Med Chem Lett* 2006;16:3170. Prisinzano, T. US Patent Appl. 2006058264. 2006. *Chem Abstr* 2006;144:292904. (g) Zjawiony J, Fahmy H, Stewart DJ, Roth B. *PCT Int. Appl. WO* 2006012643, 2006. *Chem Abstr* 2006;144:164284. (h) Harding WW, Schmidt M, Tidgewell K, Kannan P, Holden KG, Gilmour B, Navarro H, Rothman RB, Prisinzano TE. *J Nat Prod* 2006;69:107. [PubMed: 16441078] (i) Beguin C, Carlezon W, Cohen BM, He M, Lee DY-W, Richards MR. *PCT Int. Appl. WO* 2005089745, 2005. *Chem Abstr* 2005;143:326476. (j) Lee DYW, He M, Kondaveti L, Liu-Chen LY, Ma Z, Wang Y, Chen Y, Li JG, Beguin C, Carlezon WA, Cohen B. *Biorg Med Chem Lett* 2005;15:4169. (k) Lee DYW, Karnati VVR, He M, Liu-Chen LY, Kondaveti L, Ma Z, Wang Y, Chen Y, Beguin C, Carlezon WA, Cohen B. *Biorg Med Chem Lett* 2005;15:3744. (l) Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, Rothman RB, Prisinzano TE. *J Med Chem* 2005;48:4765. [PubMed: 16033256] (m) Beguin C, Richards MR, Wang Y, Chen Y, Liu-Chen LY, Ma Z, Lee DYW, Carlezon WA, Cohen BM. *Biorg Med Chem Lett* 2005;15:2761. (n) Munro TA, Rizzacasa MA, Roth BL, Toth BA, Yan F. *J Med Chem* 2005;48:345. [PubMed: 15658846] (o) Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ, Toth BA, Hufeisen SJ, Roth BL. *J Pharmacol Exp Ther* 2004;308:1197. [PubMed: 14718611] (p) Tidgewell K, Harding WW, Schmidt M, Holden KG, Murry DJ, Prisinzano TE. *Biorg Med Chem Lett* 2004;14:5099.
- Yan F, Mosier PD, Westkaemper RB, Stewart J, Zjawiony JK, Vortherms TA, Sheffler DJ, Roth BL. *Biochemistry* 2005;44:8643. [PubMed: 15952771]
- (a) Valdez LJ III, Butler WM, Hatfield GM, Paul AG, Koreeda MJ. *J Org Chem* 1984;49:4716. (b) Koreeda M, Brown L, Valdes LJ III. *Chem Lett* 1990:2015. (c) Valdez LJ III, Chang H-M, Visger DC, Koreeda M. *Org Lett* 2001;3:3935. [PubMed: 11720573]
- (a) Wallace OB, Springer DM. *Tetrahedron Lett* 1998;39:2693. (b) Yelm KE. *Tetrahedron Lett* 1999;40:1101. (c) Mastalerz H, Zhang G, Kadow J, Fairchild C, Long B, Vyas DM. *Org Lett* 2001;3:1613. [PubMed: 11405668] (d) Iimura S, Manabe K, Kobayashi S. *Org Lett* 2003;5:101. [PubMed: 12529115] (e) MacCoss RN, Henry DJ, Brain CT, Ley SV. *Synlett* 2004;4:0675. (f) Holmes BT, Snow AW. *Tetrahedron* 2005;61:12339.
- NMR and mass spectral data were obtained for all final products purified by preparative HPLC (C18 column, MeCN-water). 2-thiosalvinorin B (**5**): white solid, m.p. 201–203°C, $[\alpha]_D^{25}$ -54 (c 0.05, CHCl₃), ¹H NMR (400 MHz, CD₂Cl₂): δ 1.07 (3H, s, H-19), 1.44 (3H, s, H-20), 1.56 (4H, m, H-6b, H-7b, H-11b, SH), 1.75 (1H, m, H-6a), 2.08 (2H, m, H-7a, H-8), 2.20 (1H, m, H-3b), 2.24 (1H, s, H-10), 2.47 (1H, ddd, *J* 3, 7, 14 Hz, H-3a), 2.52 (1H, dd, *J* 5, 13 Hz, H-11a), 2.79 (1H, dd, *J* 3, 13 Hz, H-4), 3.68 (3H, s, OCH₃), 3.75 (1H, dd, *J* 6, 12 Hz, H-2), 5.53 (1H, dd, *J* 5, 12 Hz, H-12), 6.42 (1H, s, H-14), 7.44 (2H, m, H-15, H-16); ¹³C NMR (125 MHz, CDCl₃): δ 15.6 (C-20), 16.9 (C-19), 18.4 (C-7), 36.0 (C-9), 37.3 (C-3), 38.4 (C-6), 42.8 (C-5), 43.9 (C-11), 49.3 (C-2), 51.6 (C-21), 52.1 (C-8), 56.0 (C-4), 66.1 (C-10), 72.1 (C-12), 108.3 (C-14), 125.3 (C-13), 139.1 (C-16), 143.5 (C-15), 170.8 (C-17), 172.4 (C-18), 202.8 (C-1); HRESIMS *m/z* [M+H]⁺ 407.1590 (calcd for C₂₁H₂₆O₆S 406.1450).
- Procedure for synthesis of 2-epi-2-thiosalvinorin A (**7**): To suspension of (**2**) (1 mmol) in CH₂Cl₂ (5 mL) at 0°C were added excess of pyridine (1 mL) and trifluoromethanesulfonic anhydride (1.2 mmol), the reaction mixture was stirred for 20 min. The reaction solution was washed with 1N HCl and brine, dried (Na₂SO₄) and solvents were evaporated in vacuum. A mixture of obtained extract and potassium


thioacetate (5 mmol) were placed to dry acetone (10 mL) and stirred at -20°C under argon for 1 h. The reaction mixture was allowed to warm up to room temperature, concentrated in vacuum, diluted with water and extracted with chloroform. The combined organic extracts were dried (Na_2SO_4), concentrated in vacuum to give semisolid product which was purified by column chromatography (hexane/EtOAc, 2:1). Yield 75% starting from **2**, white solid, m.p. $192\text{--}194^{\circ}\text{C}$, $[\alpha]_{\text{D}}^{25} -64$ (c 0.05, CHCl_3), $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 1.15 (3H, s, H-19), 1.44 (3H, s, H-20), 1.62 (4H, m, 2H-6, H-7b, H-11b), 2.09 (3H, m, H-3b, H-7a, H-8), 2.33 (1H, s, H-10), 2.38 (3H, s, COCH_3), 2.55 (1H, dd, J 5, 13 Hz, H-11a), 2.70 (2H, m, H-3a, H-4), 3.72 (3H, s, OCH_3), 4.27 (1H, dd, J 2, 5 Hz, H-2), 5.54 (1H, dd, J 5, 11, H-12), 6.40 (1H, s, H-14), 7.42 (2H, m, H-15, H-16); $^{13}\text{C NMR}$ (100 MHz, CDCl_3): δ 15.1 (C-20), 16.4 (C-19), 18.0 (C-7), 30.6 (C-22), 31.8 (C-3), 35.2 (C-9), 38.3 (C-6), 41.9 (C-5), 43.3 (C-11), 49.7 (C-2), 51.3 (C-8), 51.8 (C-23), 52.8 (C-4), 63.8 (C-10), 72.0 (C-12), 108.4 (C-14), 125.5 (C-13), 139.3 (C-16), 143.7 (C-15), 171.2 (C-17), 172.2 (C-18), 191.1 (C-21), 203.8 (C-1); HRESIMS m/z $[\text{M}+\text{H}]^+$ 449.1687 (calcd for $\text{C}_{23}\text{H}_{28}\text{O}_7\text{S}$ 448.1556).

8. General procedure for synthesis of 2-thiosalvinorin B (**5**) and 2-epi-2-thiosalvinorin B (**8**): To a stirred solution of thioacetate (1 mmol) in methanol (10 mL) under argon at -20°C was added sodium thiomethoxide (1 equiv. 1M solution in MeOH). The reaction mixture was stirred for 30 minutes. The solution was then added to aqueous HCl (0.1M, 20 mL). The aqueous solution was extracted with CH_2Cl_2 . The combined organic layers were washed with brine, dried over Na_2SO_4 , filtered and concentrated.
9. 2-epi-2-thiosalvinorin B (**8**): white solid, m.p. $161\text{--}163^{\circ}\text{C}$, $[\alpha]_{\text{D}}^{25} -160$ (c 0.05, CHCl_3), $^1\text{H NMR}$ (400 MHz, MeOH): δ 1.12 (3H, s, H-20), 1.41 (3H, s, H-19), 1.70 (4H, m, 2H-6, H-7b, H-11b, SH), 2.03 (2H, m, H-7a, H-3b), 2.42 (1H, dd, J 3, 12 Hz, H-8), 2.52 (1H, dd, J 5, 13 Hz, H-11a), 2.68 (1H, ddd, J 6, 14, 14, H-3a), 3.08 (1H, dd, J 1, 6, H-4), 3.20 (1H, s, H-10), 3.57 (1H, d, J 6 Hz, H-2), 3.70 (3H, s, OCH_3), 5.61 (1H, dd, J 5, 11, H-12), 6.54 (1H, s, H-14), 7.50 (1H, s, H-15), 7.44 (1H, s, H-16); $^{13}\text{C NMR}$ (125 MHz, CDCl_3): δ 15.5 (C-20), 16.6 (C-19), 18.4 (C-7), 31.9 (C-3), 35.3 (C-9), 38.3 (C-6), 42.4 (C-5), 43.4 (C-2), 44.2 (C-11), 50.9 (C-4), 51.6 (C-8), 52.0 (C-21), 59.1 (C-10), 72.1 (C-12), 108.4 (C-14), 125.4 (C-13), 139.3 (C-16), 143.5 (C-15), 171.1 (C-17), 172.0 (C-18), 205.9 (C-1); HRESIMS m/z $[\text{M}+\text{H}]^+$ 407.1597 (calcd for $\text{C}_{21}\text{H}_{26}\text{O}_6\text{S}$ 406.1450).




Salvinorin A (1), R = Ac
Salvinorin B (2), R = H

Figure 1.
Salvinorins A and B




Scheme 1.
Synthesis of 2 β -chloroderivatives



Reagents and conditions: (a) NaSH, methanol, dimethylformamide, 35-40°C, 1h (44%); (b) potassium thioacetate, acetone, Δ , 3h (71%); (c) NaSMe, methanol, CH₂Cl₂, -20°C, 30min (68%); (d) Ac₂O, CH₂Cl₂, 4-DMAP (75%)

Scheme 2.
2 α -Sulfur analogs of salvinorin A



Reagents and conditions: (a) $(CF_3SO_2)_2O$, pyridine, CH_2Cl_2 , $-20^\circ C$;
 (b) potassium thioacetate, acetone, $-20^\circ C$ (75%); (c) NaSMe, methanol, CH_2Cl_2 ,
 $-20^\circ C$, 30min (70%); (d) Ac_2O , CH_2Cl_2 , 4-DMAP (78%)

Scheme 3.
 2 β -Sulfur analogs of salvinorin A

Table 1

Binding affinity of compounds **1** and **5–8** to cloned rKOR (competitive binding in the presence of [³H]U69,593) and hKOR mediated activation of intracellular calcium mobilization in HEK-293 cells.

Compounds	K _i ^a (nM)	EC ₅₀ ^b (nM)	E _{max} (%)
1	0.91	2.82±1.70	100
5	62	287±85	89±14
6	18.4±7.9	4.77±2.72	107±4
7	151±53	123±30	106±1
8	546±140	>2000	71±12

^aValues are means of three experiments, standard deviation is given in parentheses

^b*In vitro* effective concentration